A miscalculation appeared in our paper “Multi-Cancer Screening Tests: Communicating About Risks Should be Prioritized“, published in The American Journal of Medicine in April of 2021:
The number of false positive cases, correctly mentioned as being 0.5% in the 6th paragraph, was miscalculated in the next paragraph of our work (using 5% instead of 0.5%). The miscalculation is found in the 7th paragraph:
“With a 24% reduction rate of all-cancer mortality, the blood test screening strategy, within the 95,174 people in the experimental arm, would prevent 59 people of dying from cancer, while giving 4,758 people a false cancer diagnosis.”
The corrected text should read:
“With a 24% reduction rate of all-cancer mortality, the blood test screening strategy, within the 95,174 people in the experimental arm, would prevent 59 people of dying from cancer, while giving 476 people a false cancer diagnosis.”
Article Info
Publication History
Published online: May 24, 2022
Footnotes
The author would like to apologise for any inconvenience caused.
Identification
Copyright
© 2022 Elsevier Inc. All rights reserved.
ScienceDirect
Access this article on ScienceDirectLinked Article
- Multi-Cancer Screening Tests: Communicating About Risks Should be PrioritizedThe American Journal of MedicineVol. 135Issue 4
- PreviewIn June of 2021, Klein and colleagues1 reported the results of a prospective, case-controlled, observational study on the clinical validity of a multi-cancer early detection (MCED) test developed by GRAIL, Inc. Based on a blood draw providing cell-free DNA (deoxyribonucleic acid) and its interpretation through machine learning, this test has been developed with the aim of increasing the number of detected cancers through population screening. The authors reported a specificity for cancer signal detection of 99.5% and an overall sensitivity of 51.5%.
- Full-Text
- Preview
